Researchers are exploring whether anti-inflammatory medications could offer new treatment options for depression, particularly in patients exhibiting elevated levels of inflammation. This approach builds on growing evidence linking inflammation to certain forms of depression, a connection that has been investigated for several decades.

Approximately 25 percent of individuals with depression show increased levels of inflammatory proteins in their bloodstream. Studies indicate that inflammation may precede the onset of depressive symptoms, and experimental induction of inflammation in healthy volunteers has triggered transient feelings of depression and anxiety. Moreover, patients with heightened inflammation often respond poorly to conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs).

Experts suggest that inflammation may contribute to depression by altering brain chemistry. Inflammatory proteins can reduce levels of key neurotransmitters like serotonin and dopamine, affecting mood regulation. These proteins also appear to disrupt activity in brain regions involved with reward processing and motivation, which aligns with a specific symptom profile observed in inflamed depression. This subtype is characterized by somatic symptoms such as fatigue, appetite changes, disrupted sleep, and reduced pleasure or motivation (anhedonia).

In a recent small clinical trial, a drug commonly used to treat rheumatoid arthritis was tested on 30 participants with depression and high inflammation levels. While the medication led to a modest decline in depression scores—mainly in somatic symptoms—the results did not reach statistical significance compared to placebo. The study’s lead investigator described it as a "proof of concept," emphasizing the need for larger trials to better define treatment effects and patient profiles.

Similar studies have reported that anti-inflammatory treatments may benefit only those patients with elevated baseline inflammation or a history of trauma, highlighting the heterogeneity within depression diagnoses. Not all patients experience these inflammatory markers, reinforcing the notion that depression likely comprises multiple biologically distinct subtypes.

Some researchers remain cautious about the inconsistent outcomes observed across studies. Dr. Michael Irwin of the University of California, Los Angeles, noted that while experimental data strongly support a causal role for inflammation in depression, clinical trial results have been mixed and the reasons for this variability remain unclear. Other experts, like Dr. David Goldsmith of Emory University, acknowledge the evidence for an inflammatory subtype but stress that appropriate targeted treatments have yet to be identified.

Currently, major psychiatric guidelines do not recommend prescribing anti-inflammatory drugs for depression. However, some clinicians have begun measuring inflammatory markers in their patients and encouraging lifestyle interventions such as diet and exercise to reduce inflammation. This emerging perspective could eventually influence treatment strategies but has not yet become widespread.

Dr. Moira Rynn, chair of psychiatry at Duke University, described the inflammation hypothesis as compelling yet acknowledged practical challenges. Her clinic, which primarily treats individuals with resistant depression, has not yet incorporated inflammatory status into routine care but plans to explore it as more evidence accumulates. She noted that a key obstacle is the lack of clear treatment protocols based on inflammatory measures.

While investigations continue into the role of inflammation in depression, further research is needed to clarify which patients might benefit from anti-inflammatory therapies and to develop effective, personalized interventions.